Because human DPP4 inhibitors are less efficient for bacterial DPP4 (Rea et al., 2017), development of periodontopathic DPP4‐specific inhibitors and the usage for type 2 diabetes mellitus patients may synergistically reduce blood glucose concentration. Here, DPP4 is linked to type 2 diabetes mellitus.